Home › NDC Lookup › RxCUI directory › RxCUI 2672922

Ferrous bisglycinate 36.5 MG Oral Tablet — RxCUI 2672922

RxNorm drug concept · Semantic clinical drug
RxCUI 2672922 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2672922
Official nameFerrous bisglycinate 36.5 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped4
Package NDCs mapped8
Reported Medicaid activity (SDUD)3,916 prescriptions · 18 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Ferrous bisglycinate 36.5 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Ferrous bisglycinate 36.5 MG Oral Tablet RxCUI 2672922

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ferrous bisglycinate 1102188
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ferrous bisglycinate Oral Tablet 1095418
    • Ferrous bisglycinate Oral Product 1159624
    • Ferrous bisglycinate Pill 1159625
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Ferrous bisglycinate 36.5 MG 2672921
  4. Packs 5

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 13 of 13 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

4 products · 8 package NDCs
8 package NDCs map to RxCUI 2672922 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
42192-0623-03 3 BLISTER PACK in 1 CARTON (42192-623-03) / 1 KIT in 1 BLIS... levonorgestrel and ethinyl estradiol Acella Pharmaceuticals 2023-08-21
42192-0623-28 1 BLISTER PACK in 1 CARTON (42192-623-28) / 1 KIT in 1 BLIS... levonorgestrel and ethinyl estradiol Acella Pharmaceuticals 2023-08-21
70748-0322-14 3 BLISTER PACK in 1 CARTON (70748-322-14) / 1 KIT in 1 BLIS... MINZOYA Lupin Pharmaceuticals, Inc. 2025-01-09
75854-0602-02 2 BLISTER PACK in 1 CARTON (75854-602-02) / 1 KIT in 1 BLIS... Balcoltra Avion Pharmaceuticals 2018-04-10
75854-0602-03 3 BLISTER PACK in 1 CARTON (75854-602-03) / 1 KIT in 1 BLIS... Balcoltra Avion Pharmaceuticals 2018-04-10
75854-0602-28 1 BLISTER PACK in 1 CARTON (75854-602-28) / 1 KIT in 1 BLIS... Balcoltra Avion Pharmaceuticals 2018-04-10
75854-0604-01 1 BLISTER PACK in 1 CARTON (75854-604-01) / 1 KIT in 1 BLIS... AVERI Avion Pharmaceuticals, LLC 2025-06-05
75854-0604-03 3 BLISTER PACK in 1 CARTON (75854-604-03) / 1 KIT in 1 BLIS... AVERI Avion Pharmaceuticals, LLC 2025-06-05
Observed labelers: Avion Pharmaceuticals (3) · Acella Pharmaceuticals (2) · Avion Pharmaceuticals, LLC (2) · Lupin Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.